Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Hydromorphone Stories

2009-09-29 00:56:47

A Swedish researcher says drugs that may cause dose dumping, releasing medication in an unsafe manner in those who have drunk alcohol, need to be tested. Hans Lennernas, a professor in Biopharmaceutics at Uppsala University in Sweden, says some controlled release pills and capsules are susceptible to dose dumping. Lennernas says a formulation of the pain medication hydromorphone is one example of dose dumping. Testing revealed alcohol intake caused the risk of overdose and the medication has...

2009-09-23 13:52:35

Controlled release pills and capsules that show a tendency in the standard laboratory test toward "dose dumping" "” releasing their medicine in a faster and potentially unsafe manner in patients who have consumed alcohol "” should be withheld from the market until proven safe with testing in people. That's the conclusion of a review of existing studies in the September-October issue of ACS' Molecular Pharmaceutics, a bi-monthly journal. In the article, Hans Lennernäs analyzed...

2009-08-13 14:59:00

BRISTOL, Tenn., Aug. 13 /PRNewswire-FirstCall/ -- King Pharmaceuticals((R)), Inc. (NYSE: KG) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. EMBEDA(TM) is the first FDA-approved...

2009-06-17 06:00:00

CONSHOHOCKEN, PA and VANCOUVER, BC, June 17 /PRNewswire/ - Neuromed Pharmaceuticals Ltd. announced today that its subsidiary Neuromed Development Inc., has sold the U.S. rights to its lead investigational drug candidate, Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII), to Covidien's subsidiary Mallinckrodt Inc. On March 23, 2009, Neuromed announced that Exalgo met the primary endpoint in a pivotal phase III clinical trial. On May 22, 2009, Neuromed submitted a response to an...

2009-06-16 15:05:00

CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer has joined DURECT as Chief Medical Officer and Executive Vice President, Corporate Strategy. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) "Dr. Stauffer's successful leadership of clinical research and medical affairs for pain products while at Alpharma and Abbott, and first-hand experience with the regulatory approval process gained during his...

2009-06-11 08:00:00

CONSHOHOCKEN, PA and VANCOUVER, BC, June 11 /PRNewswire/ - Neuromed Pharmaceuticals Ltd. announced today that it has received notification that Merck & Co., Inc. will terminate the research collaboration and license agreement for novel compounds targeting N-type calcium channels for the treatment of pain and other disorders, which the companies entered into in March of 2006. "Over the past three years we have had an excellent and extremely productive collaboration with our colleagues at...

2009-06-10 00:21:03

A coroner in Las Vegas has ruled impressionist Danny Gans died accidentally of heart failure brought on by a toxic level of the pain killer hydromorphone. Clark County Coroner Mike Murphy would not characterize the May 1 death of the 52-year-old performer as a drug overdose, The New York Times reported Thursday. He also did not disclose the level of hydromorphone, which is marketed as Dilaudid, in Gans's system. Chip Lightman, Gans's manager, said he didn't know his client was using the...

2009-05-29 08:26:00

- Oxycodone Successfully Delivered into the Bloodstream - Data Demonstrates Sustained Release and Increased Blood Levels of Oxycodone MELBOURNE, Australia, May 29 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH; OTCQX: PPGNY) today announced the successful completion of preclinical studies related to its patented TPM/oxycodone transdermal patch system. The results of the preclinical studies demonstrated that by incorporating TPM/oxycodone into innovative patch...

2009-05-26 14:24:00

BETHESDA, Md., May 26 /PRNewswire/ -- On May 27 and 28, 2009, the Food and Drug Administration (FDA) will hear testimony about the FDA-guided effort to develop a classwide Risk Evaluation and Mitigation Strategy (REMS) for all controlled-release opioids from more than 70 patients, scientists, public health professionals, and representatives of pharmacist groups, prescriber groups, and pharmaceutical companies. Controlled-release opioids include prescription pain medications that release the...

d21e7fc30592931ebdbfffd069d9ea3c1
2009-04-10 16:22:05

Oh Thursday, the Food and Drug Administration reversed its initial plan to remove unapproved liquid morphine from being sold in the US. On March 30, the FDA decided to disallow the marketing of 14 medications, including morphine elixir, which has long been used to relieve pain in patients that are near-death. Nine companies were informed not to market the 14 unapproved narcotic pain medicines within 60 days of notification. Seven of those companies make or distribute the liquid morphine,...